KalVista Pharma Presents New Interim Results From KONFIDENT-KID Clinical Trial Evaluating EKTERLY For On-Demand Treatment Of HAE Attacks In Children Ages 2-11 At 2026 Global Angioedema Leadership Conference

KalVista Pharmaceuticals (NASDAQ: KALV) presented interim results from its KONFIDENT-KID clinical trial for EKTERLY (sebetralstat) at the 2026 Global Angioedema Leadership Conference. The trial, the largest pediatric study for hereditary angioedema (HAE), involved 33 participants and showed that sebetralstat enabled a median treatment time of 25 minutes for HAE attacks, with 67% treated within the first hour. The treatment was well tolerated, with no serious adverse events reported.